Clopidogrel and Duricef drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among people who take Clopidogrel and Duricef. Common interactions include haemoglobin increased among females and syncope among males.

The phase IV clinical study analyzes what interactions people who take Clopidogrel and Duricef have. It is created by eHealthMe based on reports of 10 people who take Clopidogrel and Duricef from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 27, 2022

10 people who take Clopidogrel and Duricef together, and have interactions are studied.

What is Clopidogrel?

Clopidogrel has active ingredients of clopidogrel. It is often used in blood clots. eHealthMe is studying from 79,598 Clopidogrel users for its effectiveness, alternative drugs and more.

What is Duricef?

Duricef has active ingredients of cefadroxil/cefadroxil hemihydrate. eHealthMe is studying from 547 Duricef users for its effectiveness, alternative drugs and more.

Number of Clopidogrel and Duricef reports submitted per year:

Clopidogrel and Duricef drug interactions.

Common Clopidogrel and Duricef drug interactions by gender *:


  1. Haemoglobin increased
  2. Fall
  3. Haematoma
  4. Haematoma infection
  5. Necrosis
  6. Pain
  7. Proteus test positive
  8. Pseudomonas infection
  9. Superinfection
  10. Wound secretion


  1. Syncope
  2. Fall
  3. Fibula fracture
  4. Fatigue
  5. Haemarthrosis
  6. Hypotension
  7. Loss of consciousness
  8. Musculoskeletal pain
  9. Pleural effusion
  10. Renal cyst

Common Clopidogrel and Duricef drug interactions by age *:
















  1. Fall
  2. Haemoglobin increased
  3. Necrosis
  4. Pain
  5. Pleural effusion
  6. Proteus test positive
  7. Pseudomonas infection
  8. Renal cyst
  9. Seizure
  10. Superinfection

Common conditions people have *:

  1. Pain: 4 people, 40.00%
  2. Vitamin B1 Decreased: 3 people, 30.00%
  3. Type 2 Diabetes: 3 people, 30.00%
  4. Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 30.00%
  5. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 30.00%
  6. Blood Magnesium Decreased: 3 people, 30.00%
  7. Cellulitis (infection under the skin): 3 people, 30.00%
  8. Chronic Kidney Disease: 3 people, 30.00%
  9. Dyslipidaemia (abnormal amount of lipids): 3 people, 30.00%
  10. Gastric Ulcer (stomach ulcer): 3 people, 30.00%

* Approximation only. Some reports may have incomplete information.

Do you take Clopidogrel and Duricef?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Clopidogrel and Duricef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Clopidogrel interactions:

Browse all interactions between Clopidogrel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on clopidogrel and cefadroxil/cefadroxil hemihydrate (the active ingredients of Clopidogrel and Duricef, respectively), and Clopidogrel and Duricef (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Clopidogrel and Duricef.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: